Special Issue

Glial Cells as Drug Targets for Schizophrenia

Message from the Guest Editors

This Special Issue focuses on how glia cell abnormality may contribute to schizophrenia and, as such, be a drug target for this illness. There is supporting evidence that oligodendrocyte dysfunction and demyelination may contribute to psychosis. Microglial activation in schizophrenia has also been reported. Astrocytes, being the most abundant cell type in the brain, release and take up several signaling molecules including neurotransmitters, antioxidants, growth factors, and cytokines, which serve to support neuronal function, the myelination state, maintenance of the blood–brain barrier, and communication with the immune system. Reactive astrocytes process and integrate neuronal activity and coordinate calcium waves, thus having the potential to alter neuronal network activity in psychosis. To our knowledge, the differential priming or susceptibility of oligodendrocytes, microglia, and/or astrocytes in psychosis is worth thoroughly investigating and may also provide some answers to the development and maintenance of schizophrenia and the development of novel agents for this illness.

Guest Editors

Prof. Dr. Kumlesh Kumar Dev
Drug Development, School of Medicine, Trinity College, Dublin, Ireland
Dr. Paraskevi Papakyriakopoulou
Department of Pharmacy, National & Kapodistrian University of Athens, Athens, Greece

Deadline for manuscript submissions

closed (15 August 2025)

Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed

mdpi.com/si/228541

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals

Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed

mdpi.com/journal/pharmaceuticals

About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.
We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter
Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

MDPI